Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn’s Disease.

Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn’s Disease. Inflamm Bowel Dis. 2019 Aug 30;: Authors: George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V Abstract BACKGROUND: We summarized the protocol-specified corticosteroid tapering regimens in clinical trials of moderate-severe ulcerative colitis (UC) and Crohn’s disease (CD) and calculated differences in rates of clinical remission vs corticosteroid-free clinical remission (CSF-CR). METHODS: Through a systematic literature review through February 28, 2019, we identified 16 randomized controlled trials (RCTs) of…

Read More

Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis.

Related Articles Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Aliment Pharmacol Ther. 2019 Sep;50(6):675-683 Authors: Sebastian S, Myers S, Argyriou K, Martin G, Los L, Fiske J, Ranjan R, Cooper B, Goodoory V, Ching HL, Jayasooriya N, Brooks J, Dhar A, Shenoy AH, Limdi JK, Butterworth J, Allen PB, Samuel S, Moran GW, Shenderey R, Parkes G, Lobo A, Kennedy NA, Subramanian S, Raine T Abstract BACKGROUND: Accelerated induction regimens of infliximab have been proposed to improve response rates in…

Read More

Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease.

Related Articles Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Sep;50(6):712-713 Authors: Zeng J, Gan HT PMID: 31456298 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31456298?dopt=Abstract

Read More

Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease-author’s reply.

Related Articles Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease-author’s reply. Aliment Pharmacol Ther. 2019 Sep;50(6):714-715 Authors: McCurdy JD PMID: 31456301 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31456301?dopt=Abstract

Read More

Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.

Related Articles Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease. J Crohns Colitis. 2019 Feb 13;: Authors: Ungaro RC, Yarur A, Jossen J, Phan BL, Chefitz E, Sehgal P, Kamal K, Bruss A, Beniwal-Patel P, Fox C, Patel A, Bahur B, Jain A, Stein D, Naik S, Dubinsky MC Abstract BACKGROUND AND AIMS: Vedolizumab is an anti-α4β7 biologic approved for ulcerative colitis [UC] and Crohn’s disease [CD]. We aimed to examine the association of maintenance vedolizumab concentrations with remission. METHODS: We performed…

Read More

Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis.

Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World J Gastroenterol. 2019 Apr 07;25(13):1603-1617 Authors: Hoffmann P, Wehling C, Krisam J, Pfeiffenberger J, Belling N, Gauss A Abstract BACKGROUND: Acute severe ulcerative colitis unresponsive to systemic steroid treatment is a life-threatening medical condition requiring hospitalization and often colectomy. Despite the increasing choice of medical therapy options for ulcerative colitis, the condition remains a great challenge in the field of inflammatory bowel diseases (IBD). The performance of the calcineurin inhibitor tacrolimus in this clinical setting is insufficiently…

Read More

Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review.

Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review. Inflamm Bowel Dis. 2019 Apr 13;: Authors: Wu B, Tong J, Ran Z Abstract Inflammatory bowel diseases are known for a chronic inflammatory process of the gastrointestinal tract and include Crohn’s disease and ulcerative colitis (UC). Patients who are dependent on or resistant to corticosteroids account for about 20% of severe UC patients. Tacrolimus is a calcineurin inhibitor that has recently been used in the treatment of steroid-refractory ulcerative colitis. Tacrolimus has been demonstrated to have remarkable therapeutic efficacy in UC patients,…

Read More

Corrigendum: Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial.

Corrigendum: Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. J Crohns Colitis. 2019 Apr 05;: Authors: Domènech E, Panés J, Hinojosa J, Annese V, Magro F, Sturniolo GC, Bossa F, Fernández F, González-Conde B, García-Sánchez V, Dignass A, Herrera JM, Cabriada JL, Guardiola J, Vecchi M, Portela F, Ginard D, ATTICA Study Group by the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa PMID: 30951596 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30951596?dopt=Abstract

Read More

Novel Leucocyte/Thrombocyte Apheresis for Induction of Steroid-Free Remission in Ulcerative Colitis: A Controlled Randomized Pilot Study.

Related Articles Novel Leucocyte/Thrombocyte Apheresis for Induction of Steroid-Free Remission in Ulcerative Colitis: A Controlled Randomized Pilot Study. J Crohns Colitis. 2019 Mar 13;: Authors: Kruis W, Nguyen P, Morgenstern J, Ramlow W, Dignaß A, Stallmach A, Drebber U Abstract BACKGROUND AND AIMS: In active ulcerative colitis [UC] refractory to mesalazine, escalation to either steroids or immunosuppression is common practice. The efficacy and safety of alternative escalation therapy with a novel leukocyte apheresis device were studied. METHODS: This was a prospective, randomized, controlled multicentre pilot study comparing leukocyte apheresis with…

Read More
<< Go Back